Ocugen's Series B Round

Ocugen raised a round of funding on June 13, 2017.

Ocugen is advancing two novel biologicals and a marketed drug product as a re-purposed drug under the U.S. Food and Drug Administration's 505(b)(2) regulatory pathway to treat sight threatening ocular…

Articles about Ocugen's Series B Round: